Effect of Calcimimetic Agent, KRN568, on Gastrin Secretion in Healthy Subjects
KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extrac...
Saved in:
Published in: | ENDOCRINE JOURNAL Vol. 47; no. 5; pp. 517 - 523 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Japan
The Japan Endocrine Society
2000
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8ng/ml) compared to the other 5 individuals (Cmax 6.5±2.2 and 7.4±1.6ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34±6 to 63±3pg/ml) after oral administration of 400mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound. |
---|---|
AbstractList | KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently carried out in Japan. Single doses of KRN568, ranging from 25 mg to 400 mg, were orally administered to 6 healthy male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8 ng/ml) compared to the other 5 individuals (Cmax 6.5 plus or minus 2.2 and 7.4 plus or minus 1.6 ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125 pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34 plus or minus 6 to 63 plus or minus 3 pg/ml) after oral administration of 400 mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound. KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently carried out in Japan. Single doses of KRN568, ranging from 25 mg to 400 mg, were orally administered to 6 healthy male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8 ng/ml) compared to the other 5 individuals (Cmax 6.5 +/- 2.2 and 7.4+/- 1.6 ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125 pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34 +/- 6 to 63 +/- 3 pg/ml) after oral administration of 400 mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound. KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8ng/ml) compared to the other 5 individuals (Cmax 6.5±2.2 and 7.4±1.6ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34±6 to 63±3pg/ml) after oral administration of 400mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound. KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level . However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently carried out in Japan. Single doses of KRN568, ranging from 25 mg to 400 mg, were orally administered to 6 healthy male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90. 8 and non-fasting 83. 8 ng/ml) compared to the other 5 individuals (Cmax 6. 5±2. 2 and 7. 4±1. 6 ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125 pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34±6 to 63±3 pg/ml) after oral administration of 400 mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound. |
Author | AZUMA, JUNICHI IGARASHI, TETSUYA MARUYAMA, KAZUNOBU FUKUDA, TSUYOSHI OGATA, ETSURO |
Author_xml | – sequence: 1 fullname: IGARASHI, TETSUYA organization: Department of Internal Medicine, University of Tokyo Branch Hospital, University of Tokyo – sequence: 2 fullname: OGATA, ETSURO organization: Cancer Institute Hospital – sequence: 3 fullname: MARUYAMA, KAZUNOBU organization: Osaka Pharmacology Research Clinic – sequence: 4 fullname: FUKUDA, TSUYOSHI organization: Clinical Evaluation of Medicines and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University – sequence: 5 fullname: AZUMA, JUNICHI organization: Clinical Evaluation of Medicines and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11200930$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUFP3DAQRq0KVBbKtccqp57IYnvs2DmiFSxVEZVKOVuO14ZEiQN2cuDfM5ClPfbikT3Pz6PPx-QgjtET8pXRNZNUnfu4G13q1kKtJVOfyIqB0KWQgh6QFa2ZLnUt6yNynHNHKYAU8JkcMcYprYGuyO1lCN5NxRiKje1dO7SDn1pXXDz4OJ0VP3_fykqfFWMstjZPqY3FnXcJETzBzbW3_fT4UtzNTYea_IUcBttnf7qvJ-T-6vLP5rq8-bX9sbm4KV2l5VRqGyRvODR1DRXjsgYRtFA8aKmAMS0b5naBQuNBYU9rUUkquFWiwoYIcEK-L96nND7PPk9maLPzfW-jH-dsFJcgAcR_QaaZrBVnCK4X0KUx5-SDeUrtYNOLYdS8RW32URuhDEaNF77tzXMz-N0_fJ8tAlcLgN3W2X6MfRu96cY5RczGuOfqXWmQp4ZSoajEwg1FPS4cGHBOKxRtF1GXJ_vg_75kE_5U7z8GYxjm-3DL8ib5INyjTYjBK_UOqS0 |
CitedBy_id | crossref_primary_10_1007_s00198_008_0637_8 crossref_primary_10_1016_j_ceca_2003_10_020 crossref_primary_10_1111_bph_12420 crossref_primary_10_1016_j_pharmthera_2005_06_019 crossref_primary_10_1051_medsci_20042011973 crossref_primary_10_1359_JBMR_051210 crossref_primary_10_1007_s00467_009_1153_6 crossref_primary_10_1016_j_bone_2004_03_021 crossref_primary_10_1053_gast_2001_23246 |
ContentType | Journal Article |
Copyright | The Japan Endocrine Society |
Copyright_xml | – notice: The Japan Endocrine Society |
CorporateAuthor | University of Tokyo Branch Hospital Department of Internal Medicine University of Tokyo Cancer Institute Hospital Clinical Evaluation of Medicines and Therapeutics Osaka University Graduate School of Pharmaceutical Sciences Osaka Pharmacology Research Clinic |
CorporateAuthor_xml | – name: University of Tokyo Branch Hospital – name: University of Tokyo – name: Osaka University – name: Cancer Institute Hospital – name: Osaka Pharmacology Research Clinic – name: Graduate School of Pharmaceutical Sciences – name: Department of Internal Medicine – name: Clinical Evaluation of Medicines and Therapeutics |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7X8 |
DOI | 10.1507/endocrj.47.517 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | Calcium & Calcified Tissue Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1348-4540 |
EndPage | 523 |
ExternalDocumentID | 10_1507_endocrj_47_517 11200930 cq6endoc_2000_004705_002_0517_0523132206 article_endocrj1993_47_5_47_5_517_article_char_en |
Genre | Clinical Trial Journal Article |
GroupedDBID | --- .55 .GJ 29G 2WC 3O- 53G 5GY 5RE AAEJM AAUGY ACPRK ACRZS ADBBV AENEX AJJEV ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP CS3 DIK DU5 E3Z EBD EBS EJD EMOBN F5P JMI JSF JSH KQ8 MOJWN M~E OK1 P2P RJT RNS RZJ SV3 TKC TR2 X7M XSB ZGI ZXP AFPKN GROUPED_DOAJ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7X8 |
ID | FETCH-LOGICAL-c685t-8af52b23b9936125934f8472f85731185b1cdf03be3793488465042a7461cd4f3 |
ISSN | 0918-8959 |
IngestDate | Sat Aug 17 00:49:52 EDT 2024 Fri Aug 16 08:02:00 EDT 2024 Thu Nov 21 21:00:54 EST 2024 Sat Sep 28 08:40:21 EDT 2024 Fri Nov 08 06:50:52 EST 2024 Thu Aug 17 20:29:52 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c685t-8af52b23b9936125934f8472f85731185b1cdf03be3793488465042a7461cd4f3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/endocrj1993/47/5/47_5_517/_article/-char/en |
PMID | 11200930 |
PQID | 18159721 |
PQPubID | 23462 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_72535334 proquest_miscellaneous_18159721 crossref_primary_10_1507_endocrj_47_517 pubmed_primary_11200930 medicalonline_journals_cq6endoc_2000_004705_002_0517_0523132206 jstage_primary_article_endocrj1993_47_5_47_5_517_article_char_en |
PublicationCentury | 2000 |
PublicationDate | 2000-00-00 |
PublicationDateYYYYMMDD | 2000-01-01 |
PublicationDate_xml | – year: 2000 text: 2000-00-00 |
PublicationDecade | 2000 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | ENDOCRINE JOURNAL |
PublicationTitleAlternate | Endocr J |
PublicationYear | 2000 |
Publisher | The Japan Endocrine Society |
Publisher_xml | – name: The Japan Endocrine Society |
References | 2). Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, Del Mar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95: 4040-4045. 5). Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 5: 215-223. 11). Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83: 1083-1088. 6). de Morais SMF, Wilkinson GR, Blaisdell GRJ, Nakamura K, Meyer UA, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598. 8). Brown EM, Pollak M, Hebert SC (1998) The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 49: 15-29. 18). Hoensch HP, Hutzel H, Kirch W, Ohnhaus EE (1985) Isolation of human hepatic microsomes and their inhibition by cimetidine and ranitidine. Eur J Clin Pharmacol 29: 199-206. 4). Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J (1999) Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47: 450-453. 7). Zhou Q, Yamamoto I, Fukuda T, Ohno M, Sumida A, Azuma J (1999) CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Eur J Clin Pharmacol 55: 43-47. 17). Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-289. 9). Cheng I, Qureshi I, Chattopadhyay N, Qureshi A, Butters RR, Hall AE, Cima RR, Rogers KV, Hebert SC, Geibel JP, Brown EM, Soybel DI (1999) Expression of an extracellular calcium-sensing receptor in rat stomach. Gastroenterology 116: 118-126. 1). Bloom SR, Polak JM (1995) The endocrine gastrointestinal tract: Pathophysiology. In Principles and Practice of Endocrinology and Metabolism. Becker KL (ed) JB Lippincott Co., Philadelphia, 1499-1512. 14). Lamers CG, Van Tongeren JH (1977) Comparative study of the value of the calcium, secretin, and meal stimulated increase in serum gastrin to the diagnosis of the Zollinger-Ellison syndrome. Gut 18: 128-135. 16). Nishida Y, Fukuda T, Yamamoto I, Azuma J (2000) The CYP2D6 genotypes in a Japanese population; low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics (in press). 19). Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol 46: 452-459. 12). Silverberg SJ, Bone HG, 3rd, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL, Bilezikian JP (1997) Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337: 1506-1510. 3). Ray JM, Squires PE, Curtis SB, Meloche MR,Buchan AM (1997) Expression of the calcium-sensing receptor on human antral gastrin cells in culture. J Clin Invest 99: 2328-2333. 10). Nemeth EF, Fox J (1999) Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends in Endocrinology and Metabolism 10: 66-71. 15). Coburn JW, Maung HM (2000) Calcimimetic agents and the calcium-sensing receptor. Curr Opin Nephrol Hypertens 9: 123-132. 13). Antonsen JE, Sherrard DJ, Andress DL (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 53: 223-227. |
References_xml | |
SSID | ssj0033543 ssib022572652 ssib002822051 ssib000750009 |
Score | 1.6527995 |
Snippet | KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has... |
SourceID | proquest crossref pubmed medicalonline jstage |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 517 |
SubjectTerms | Administration, Oral Adult Aniline Compounds - pharmacokinetics Aniline Compounds - pharmacology Calcimimetics Calcium - agonists Calcium-sensing receptor Cytochrome P-450 Enzyme System - genetics Gastrin Gastrins - blood Gastrins - metabolism Genotype Humans Male Phenethylamines Polymerase Chain Reaction Polymorphism, Restriction Fragment Length Propylamines |
Title | Effect of Calcimimetic Agent, KRN568, on Gastrin Secretion in Healthy Subjects |
URI | https://www.jstage.jst.go.jp/article/endocrj1993/47/5/47_5_517/_article/-char/en http://mol.medicalonline.jp/en/journal/download?GoodsID=cq6endoc/2000/004705/002&name=0517-0523e https://www.ncbi.nlm.nih.gov/pubmed/11200930 https://search.proquest.com/docview/18159721 https://search.proquest.com/docview/72535334 |
Volume | 47 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Endocrine Journal, 2000, Vol.47(5), pp.517-523 |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6gRASQnyvfPoBiYcuWxp_xH0CxFoNsXUSdNLeLOer2lhTaJaH_ffc2U7aCE3AAy9pmtpWcverc3e--5mQtwCaXGaKB7m0pNpSBGooM3BVWIbvJyPtXgSH3-LpmToY83Gv19BArK_9V03DNdA1Vs7-g7bbQeECnIPO4Qhah-Nf6d3TEWO2uLlMzxfni9xysmIJlf1Xf50KqfAM9D43uG1HOajQeGzSHl1p5PWgqhMM0lSd4H2ZLVMsGBxs3gxCa25WuC9TJ-_6ZG6ccdqWOxybVX1tFqYTYJ3U3-vMrHs2QYhwM444VIEaeVpvP6U6Ek0PHbExPwpXqOlftcKVGv82iwubuJHbJ7rY4_Fe222TLnt6oienR0d6Nj6bbZFbEcw0uIXFwecvzauYMeHSJpt79KydMP5-d_SOVXL7AgxzZFy4t3CLZY605GYfxNoiswfkvnci6Een_Yekl5ePyJ1jnybxmEwdCOiyoJsgoBYEu9RBYJcuS-oBQFsAUPjiAUAbADwhp5Px7NNh4DfOCFKpxFWgTCGiJGIJGJ9owY4YL8AKiQolYgYepUiGaVaELMkZCA2mcA52Oo9MzCX8wAv2lGyXyzLfITROR0oa8Mt5mHORF6pI0wxcYAmyTdJI9sm7RnD6h-NH0ehXgoi1F7HmsQYR98kHJ9e2nf-PNO0wldS2dQfo0rbACkRo1ifvOxrRHuqVTn9KOwruqop8tzwOBXxEGinoNC59YNQlhNt90-hQwzyKi2OmzJd1pcHSFchkdXOLOBIMC9f75JlT_vqBh7jGyMLnf-z7gtx1XA4Yw3tJtq9Wdf6KbFVZ_doi9xfiG6Cr |
link.rule.ids | 315,782,786,4028,27932,27933,27934 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+calcimimetic+agent%2C+KRN568%2C+on+gastrin+secretion+in+healthy+subjects&rft.jtitle=Endocrine+journal&rft.au=Igarashi%2C+T&rft.au=Ogata%2C+E&rft.au=Maruyama%2C+K&rft.au=Fukuda%2C+T&rft.date=2000&rft.issn=0918-8959&rft.volume=47&rft.issue=5&rft.spage=517&rft.epage=523&rft_id=info:doi/10.1507%2Fendocrj.47.517&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-8959&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-8959&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-8959&client=summon |